Transcriptional network profile on synovial fluid T cells in psoriatic arthritis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Rheumatology

• Publication date

  2015-07-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10067-015-3002-2PMID 26152611
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-1 signaling modulates STAT activation to antagonize retinoic acid signaling and control Th17–iTreg balance

  2015influential reference
• IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis

  2015cited by this paper
• JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis

  2014cited by this paper
• JAK2-STAT3 Blockade by AG490 Suppresses Autoimmune Arthritis in Mice via Reciprocal Regulation of Regulatory T Cells and Th17 Cells

  2014cited by this paper
• Novel Treatments with Small Molecules in Psoriatic Arthritis

  2014cited by this paper
• T cell-intrinsic role of IL-6 signaling in primary and memory responses

  2014cited by this paper
• Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis

  2014cited by this paper
• Essentials of Th17 cell commitment and plasticity.

  2013cited by this paper
• Transcription factor interplay in T helper cell differentiation

  2013cited by this paper
• The plasticity and stability of regulatory T cells

  2013cited by this paper
• Th17 and Th22 cells in psoriatic arthritis and psoriasis

  2013cited by this paper
• T cells out of control—impaired immune regulation in the inflamed joint

  2013cited by this paper
• The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

  2013cited by this paper
• Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis

  2013cited by this paper
• The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

  2012cited by this paper
• Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses

  2012cited by this paper
• IL-6 activates STAT5 in T cells.

  2012cited by this paper
• Regulatory T cells: mechanisms of differentiation and function.

  2012cited by this paper
• Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity.

  2012cited by this paper
• FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis

  2012cited by this paper
• The inflammatory milieu in the rheumatic joint reduces regulatory T‐cell function

  2011cited by this paper
• Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

  2011cited by this paper
• Genomic views of STAT function in CD4+ T helper cell differentiation

  2011cited by this paper
• Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5

  2011cited by this paper
• Stat3 Phosphorylation Mediates Resistance of Primary Human T Cells to Regulatory T Cell Suppression

  2011cited by this paper
• Synovial and Peripheral Blood CD4+FoxP3+ T Cells in Spondyloarthritis

  2011cited by this paper
• Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.

  2011cited by this paper
• Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL

  2010cited by this paper
• Generation of Pathogenic Th17 Cells in the Absence of TGF-β Signaling

  2010cited by this paper
• The transient nature of the Th17 phenotype

  2010cited by this paper
• IL-1β–Mediated Signals Preferentially Drive Conversion of Regulatory T Cells but Not Conventional T Cells into IL-17–Producing Cells

  2010cited by this paper
• Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint

  2010cited by this paper
• Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity.

  2010cited by this paper
• The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo

  2009cited by this paper
• A Dual Action of Rheumatoid Arthritis Synovial Fibroblast IL-15 Expression on the Equilibrium between CD4+CD25+ Regulatory T Cells and CD4+CD25− Responder T Cells1

  2009cited by this paper
• Janus kinases in immune cell signaling

  2009cited by this paper
• IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells1

  2009cited by this paper
• STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells.

  2008cited by this paper
• Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.

  2008cited by this paper
• IL-2 Receptor β-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells1

  2007cited by this paper
• Cutting Edge: Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17+ T Cell Pool IL-1 Subverts IL-2-Mediated Suppression1

  2007cited by this paper
• Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells

  2006cited by this paper
• Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease

  2006cited by this paper
• Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

  2006cited by this paper
• Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

  2006cited by this paper
• Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells.

  2006cited by this paper
• Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment

  2006cited by this paper
• Dysfunctional Blood and Target Tissue CD4+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation1

  2005cited by this paper
• CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease

  2004cited by this paper
• Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

  2003cited by this paper
• A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1

  2002cited by this paper
• An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT

  1997cited by this paper
• Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.

  1997cited by this paper
• Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.

  1995cited by this paper
• A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin‐6.

  1995cited by this paper
• Expression of interleukin-6 receptor on blood lymphocytes without in vitro activation.

  1992cited by this paper
• LymphocytesFine-Tuning IL-17A Production in CD4 T The Role of IL-15 in Activating STAT5 and

  year unknowncited by this paper

• Risk of Major Adverse Cardiovascular Events and Thromboembolism Events in Patients with Psoriatic Arthritis on JAK Inhibitors: A Network Meta-Analysis

  2025cites this paper
• Precision medicine using molecular-target drugs in psoriatic arthritis

  2025cites this paper
• IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies

  2025cites this paper
• The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis

  2024cites this paper
• Early psoriatic arthritis: clinical and therapeutic challenges

  2024cites this paper
• The ‘Treg paradox’ in inflammatory arthritis

  2024cites this paper
• JAK Inhibitors in Psoriatic Disease

  2023cites this paper
• Recent developments for new investigational JAK inhibitors in psoriatic arthritis

  2023cites this paper
• Analysis of rheumatoid- vs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3/4 and FOXP3) activation.

  2022cites this paper
• High Dimensional Analyses of Circulating Immune Cells in Psoriatic Arthritis Detects Elevated Phosphorylated STAT3

  2022cites this paper
• Psoriatic arthritis from a mechanistic perspective

  2022cites this paper
• Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3intCD161 + RORγt + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies

  2022cites this paper
• Peripheral T_reg Levels and Transforming Growth Factor-β (TGFβ) in Patients with Psoriatic Arthritis: A Systematic Review Meta-Analysis

  2022cites this paper
• Adaptive Immune-Related Cells and Cytokines in Spondyloarthropathies

  2021cites this paper
• Patterns of T‐Cell Phenotypes in Rheumatic Diseases From Single‐Cell Studies of Tissue

  2021cites this paper
• Traitor or warrior-Treg cells sneaking into the lesions of psoriatic arthritis.

  2020cites this paper
• Emerging systemic drugs in the treatment of plaque psoriasis

  2020cites this paper
• Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art

  2020cites this paper
• Metabolic Syndrome and psoriatic arthritis: considerations for the clinician

  2020cites this paper
• Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future

  2020cites this paper
• Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis

  2019cites this paper
• Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management

  2019cites this paper
• An evaluation of tofacitinib for the treatment of psoriatic arthritis

  2019cites this paper
• Psoriatic Arthritis and Infection

  2019cites this paper
• Tofacitinib: A Review in Psoriatic Arthritis

  2019cites this paper
• Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs

  2018cites this paper
• Regulatory T Cell Plasticity and Stability and Autoimmune Diseases

  2018cites this paper
• Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”

  2018cites this paper
• Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis

  2018cites this paper
• Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.

  2017cites this paper
• Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence

  2017cites this paper
• Inflammatory cytokines compromise programmed cell death‐1 (PD‐1)‐mediated T cell suppression in inflammatory arthritis through up‐regulation of soluble PD‐1

  2017cites this paper
• Small molecule therapy for managing moderate to severe psoriatic arthritis

  2017cites this paper
• Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints

  2017cites this paper
• Psoriatic Disease 10 Years Later

  2017cites this paper
• Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study

  2016cites this paper
• Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis

  2016cites this paper
• Signal Transduction Networks Analysis: The Reverse Phase Protein Array

  2016cites this paper
• Emerging drugs for psoriatic arthritis

  2016cites this paper
• Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy.

  2016cites this paper
• Psoriatic arthritis and psoriasis: differential diagnosis

  2016cites this paper
• Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints

  2015cites this paper